Florent Soubrier

List of Publications by Citations

37 papers	3,247 citations	24 h-index	40 g-index
40 ext. papers	4,054 ext. citations	14.3 avg, IF	4.45 L-index

#	Paper	IF	Citations
37	Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. *Human Mutation*, **2006**, 27, 121-32	4.7	322
36	A novel channelopathy in pulmonary arterial hypertension. *New England Journal of Medicine*, **2013**, 369, 351-361	59.2	311
35	EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. *Nature Genetics*, **2014**, 46, 65-9	36.3	259
34	Genetics and genomics of pulmonary arterial hypertension. *Journal of the American College of Cardiology*, **2013**, 62, D13-21	15.1	228
33	Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 177, 1377-83	10.2	225
32	Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 181, 851-61	10.2	209
31	BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. *Lancet Respiratory Medicine,the*, **2016**, 4, 129-37	35.1	202
30	Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. *Nature Communications*, **2018**, 9, 1416	17.4	182
29	Genetics and genomics of pulmonary arterial hypertension. *European Respiratory Journal*, **2019**, 53,	13.6	179
28	Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects. *Human Mutation*, **2015**, 36, 1113-27	4.7	142
27	Pulmonary veno-occlusive disease. *European Respiratory Journal*, **2016**, 47, 1518-34	13.6	134
26	Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. *Human Mutation*, **2011**, 32, 1385-9	4.7	116
25	Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. *Nature Genetics*, **2013**, 45, 518-21	36.3	82
24	Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. *Lancet Respiratory Medicine,the*, **2017**, 5, 125-134	35.1	76
23	Phenotypic Characterization of Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. *Circulation*, **2017**, 136, 2022-2033	16.7	75
22	Genetic counselling in a national referral centre for pulmonary hypertension. *European Respiratory Journal*, **2016**, 47, 541-52	13.6	63
21	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. *Lancet Respiratory Medicine,the*, **2019**, 7, 227-238	35.1	55

20	Genetic analyses in a cohort of children with pulmonary hypertension. *European Respiratory Journal* , **2016**, 48, 1118-1126	13.6	54
19	BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension. *European Respiratory Journal*, **2016**, 48, 1668-1681	13.6	49
18	Characterization of Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 575-585	10.2	46
17	Widening the landscape of heritable pulmonary hypertension mutations in paediatric and adult cases. *European Respiratory Journal*, **2019**, 53,	13.6	37
16	Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations. *European Respiratory Journal*, **2014**, 44, 1069-72	13.6	33
15	Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. *Journal of Heart and Lung Transplantation*, **2018**, 37, 647-655	5.8	31
14	Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of bone morphogenetic protein receptor type 2. *Chest*, **2015**, 147, 1385-1394	5.3	26
13	Familial pulmonary arterial hypertension by heterozygous loss of function. *European Respiratory Journal*, **2020**, 55,	13.6	23
12	Clinical and genetic findings in children with central nervous system arteriovenous fistulas. *Annals of Neurology*, **2017**, 82, 972-980	9.4	20
11	Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension. *European Respiratory Journal*, **2020**, 55,	13.6	12
10	Phenotype and outcome of pulmonary arterial hypertension patients carrying a mutation. *European Respiratory Journal*, **2020**, 55,	13.6	11
9	Screening for pulmonary arterial hypertension in adults carrying a mutation. *European Respiratory Journal*, **2021**, 58,	13.6	11
8	Bayesian Inference Associates Rare Variants with Specific Phenotypes in Pulmonary Arterial Hypertension. *Circulation Genomic and Precision Medicine*, **2020**,	5.2	9
7	From an ACE polymorphism to genome-wide searches for eQTL. *Journal of Clinical Investigation*, **2013**, 123, 111-2	15.9	7
6	Mendelian randomisation and experimental medicine approaches to IL-6 as a drug target in PAH. *European Respiratory Journal*, **2021**,	13.6	6
5	Bayesian inference associates rare KDR variants with specific phenotypes in pulmonary arterial hypertension		3
4	Higher prevalence of splenic artery aneurysms in hereditary hemorrhagic telangiectasia: Vascular implications and risk factors. *PLoS ONE*, **2020**, 15, e0226681	3.7	2
3	Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. *Nature Communications*, **2021**, 12, 7104	17.4	1

2	Arteriovenous Cerebral High Flow Shunts in Children: From Genotype to Phenotype.. *Frontiers in Pediatrics*, **2022**, 10, 871565	3.4	1
1	A CELSR1 variant in a patient with pulmonary arterial hypertension. *Clinical Genetics*, **2021**, 100, 771-772	4	0